{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:16:49Z","timestamp":1790482609240,"version":"4.1.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004955","name":"Austrian Research Promotion Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>A vaccine (HB-101) consisting of 2 nonreplicating lymphocytic choriomeningitis virus (LCMV) vectors expressing the human cytomegalovirus antigens glycoprotein B (gB) and the 65-kD phosphoprotein (pp65), respectively, is in development to prevent cytomegalovirus infection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>HB-101 was tested in cytomegalovirus-naive, healthy adults in a randomized, double-blind, placebo-controlled, dose-escalation Phase I trial. Fifty-four subjects received low, medium, or high dose of HB-101 or placebo by intramuscular administration at Month 0, 1, and 3. Safety and immunogenicity were the respective primary and secondary endpoints. Subjects were followed for 12 months after the initial immunization.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Vaccination was associated with transient mild to moderate adverse events. HB-101 administration induced dose-dependent gB- and pp65-specific cellular responses, dominated by pp65-specific CD8 T cells, a high fraction of which were polyfunctional. Two administrations were sufficient to elicit dose-dependent gB-binding and cytomegalovirus-neutralizing antibodies (Abs). Cytomegalovirus-specific immune responses were boosted after each administration. Only 1 of 42 vaccine recipients mounted a transient LCMV vector-neutralizing Ab response.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>HB-101 was well tolerated and induced cytomegalovirus-specific polyfunctional CD8 T-cell and neutralizing Ab responses in the majority of subjects. Lack of vector-neutralizing Ab responses should facilitate booster vaccinations. These results justify further clinical evaluation of this vaccine candidate.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiaa121","type":"journal-article","created":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T12:09:06Z","timestamp":1584706146000},"page":"1399-1410","source":"Crossref","is-referenced-by-count":35,"title":["A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus"],"prefix":"10.1093","volume":"225","author":[{"given":"Michael","family":"Schwendinger","sequence":"first","affiliation":[{"name":"Hookipa Pharma Inc., New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Thiry","sequence":"additional","affiliation":[{"name":"Hookipa Pharma Inc., New York, New York, USA"},{"name":"Senergues Consult, Saint Etienne de Maurs, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"De Vos","sequence":"additional","affiliation":[{"name":"Bejamad bvba, Consultancy Office Pharmaceutical Sciences, Dworp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Leroux-Roels","sequence":"additional","affiliation":[{"name":"Center for Vaccinology (CEVAC), Ghent University Hospital, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Bruhwyler","sequence":"additional","affiliation":[{"name":"ECSOR, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Huygens","sequence":"additional","affiliation":[{"name":"Caprion Biosciences, Gosselies, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Ganeff","sequence":"additional","affiliation":[{"name":"Caprion Biosciences, Gosselies, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidemarie","family":"Buchinger","sequence":"additional","affiliation":[{"name":"Hookipa Pharma Inc., New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus K","family":"Orlinger","sequence":"additional","affiliation":[{"name":"Hookipa Pharma Inc., New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D","family":"Pinschewer","sequence":"additional","affiliation":[{"name":"Hookipa Pharma Inc., New York, New York, USA"},{"name":"University of Basel, Department of Biomedicine \u2013 Haus Petersplatz, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P","family":"Monath","sequence":"additional","affiliation":[{"name":"Hookipa Pharma Inc., New York, New York, USA"},{"name":"Crozet BioPharma LLC, Devens, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders E","family":"Lilja","sequence":"additional","affiliation":[{"name":"Hookipa Pharma Inc., New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,21]]},"reference":[{"key":"2022041907565483700_CIT0001","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/rmv.655","article-title":"Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection","volume":"20","author":"Cannon","year":"2010","journal-title":"Rev Med Virol"},{"key":"2022041907565483700_CIT0002","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1399-3062.2009.00372.x","article-title":"Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation","volume":"11","author":"Fisher","year":"2009","journal-title":"Transpl Infect Dis"},{"key":"2022041907565483700_CIT0003","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/rmv.535","article-title":"Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection","volume":"17","author":"Kenneson","year":"2007","journal-title":"Rev Med Virol"},{"key":"2022041907565483700_CIT0004","doi-asserted-by":"crossref","first-page":"e00268-17","DOI":"10.1128\/CVI.00268-17","article-title":"Progress toward development of a vaccine against congenital cytomegalovirus infection","volume":"24","author":"Schleiss","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"2022041907565483700_CIT0005","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/14760584.2018.1526085","article-title":"A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection","volume":"17","author":"Diamond","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"2022041907565483700_CIT0006","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1128\/JVI.01251-08","article-title":"Human cytomegalovirus glycoprotein B is required for virus entry and cell-to-cell spread but not for virion attachment, assembly, or egress","volume":"83","author":"Isaacson","year":"2009","journal-title":"J Virol"},{"key":"2022041907565483700_CIT0007","doi-asserted-by":"crossref","first-page":"e1002172","DOI":"10.1371\/journal.ppat.1002172","article-title":"B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies","volume":"7","author":"P\u00f6tzsch","year":"2011","journal-title":"PLoS Pathog"},{"key":"2022041907565483700_CIT0008","doi-asserted-by":"crossref","first-page":"8176","DOI":"10.1038\/ncomms9176","article-title":"Structure of HCMV glycoprotein B in the postfusion conformation bound to a neutralizing human antibody","volume":"6","author":"Chandramouli","year":"2015","journal-title":"Nat Commun"},{"key":"2022041907565483700_CIT0009","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.1073\/pnas.1800224115","article-title":"Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies","volume":"115","author":"Baraniak","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022041907565483700_CIT0010","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.vaccine.2015.11.056","article-title":"Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: a randomized clinical trial","volume":"34","author":"Bernstein","year":"2016","journal-title":"Vaccine"},{"key":"2022041907565483700_CIT0011","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","article-title":"Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial","volume":"377","author":"Griffiths","year":"2011","journal-title":"Lancet"},{"key":"2022041907565483700_CIT0012","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00006454-200202000-00009","article-title":"Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers","volume":"21","author":"Mitchell","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"2022041907565483700_CIT0013","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1073\/pnas.1800177115","article-title":"HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions","volume":"115","author":"Nelson","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022041907565483700_CIT0014","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jcv.2009.07.002","article-title":"Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant","volume":"46","author":"Pass","year":"2009","journal-title":"J Clin Virol"},{"key":"2022041907565483700_CIT0015","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1086\/315022","article-title":"A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant","volume":"180","author":"Pass","year":"1999","journal-title":"J Infect Dis"},{"key":"2022041907565483700_CIT0016","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa0804749","article-title":"Vaccine prevention of maternal cytomegalovirus infection","volume":"360","author":"Pass","year":"2009","journal-title":"N Engl J Med"},{"key":"2022041907565483700_CIT0017","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/infdis\/jir138","article-title":"Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women","volume":"203","author":"Sabbaj","year":"2011","journal-title":"J Infect Dis"},{"key":"2022041907565483700_CIT0018","doi-asserted-by":"crossref","first-page":"7569","DOI":"10.1128\/jvi.70.11.7569-7579.1996","article-title":"The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL","volume":"70","author":"Wills","year":"1996","journal-title":"J Virol"},{"key":"2022041907565483700_CIT0019","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1086\/588385","article-title":"Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects","volume":"197","author":"Wloch","year":"2008","journal-title":"J Infect Dis"},{"key":"2022041907565483700_CIT0020","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1473-3099(11)70344-9","article-title":"A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"12","author":"Kharfan-Dabaja","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"2022041907565483700_CIT0021","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1111\/ajt.14925","article-title":"A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor","volume":"18","author":"Vincenti","year":"2018","journal-title":"Am J Transplant"},{"key":"2022041907565483700_CIT0022","article-title":"Additive protection against congenital cytomegalovirus conferred by combined glycoprotein B\/pp65 vaccination using a lymphocytic choriomeningitis virus vector","volume":"24:e00300-16","author":"Schleiss","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"2022041907565483700_CIT0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vaccine.2016.11.063","article-title":"Development of novel replication-defective lymphocytic choriomeningitis virus vectors expressing SIV antigens","volume":"35","author":"Penaloza MacMaster","year":"2017","journal-title":"Vaccine"},{"key":"2022041907565483700_CIT0024","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/nm.2104","article-title":"Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity","volume":"16","author":"Flatz","year":"2010","journal-title":"Nat Med"},{"key":"2022041907565483700_CIT0025","doi-asserted-by":"crossref","first-page":"7760","DOI":"10.1128\/JVI.00599-12","article-title":"Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates","volume":"86","author":"Flatz","year":"2012","journal-title":"J Virol"},{"key":"2022041907565483700_CIT0026","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1128\/JCM.36.11.3337-3341.1998","article-title":"Development of a new cytomegalovirus (CMV) immunoglobulin M (IgM) immunoblot for detection of CMV-specific IgM","volume":"36","author":"Lazzarotto","year":"1998","journal-title":"J Clin Microbiol"},{"key":"2022041907565483700_CIT0027","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jviromet.2017.08.004","article-title":"Clinical evaluation of the new Roche platform of serological and molecular cytomegalovirus-specific assays in the diagnosis and prognosis of congenital cytomegalovirus infection","volume":"248","author":"Chiereghin","year":"2017","journal-title":"J Virol Methods"},{"key":"2022041907565483700_CIT0028","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0166-4328(01)00297-2","article-title":"Controlling the false discovery rate in behavior genetics research","volume":"125","author":"Benjamini","year":"2001","journal-title":"Behav Brain Res"},{"key":"2022041907565483700_CIT0029","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2022041907565483700_CIT0030","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1086\/319680","article-title":"A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects","volume":"183","author":"Berencsi","year":"2001","journal-title":"J Infect Dis"},{"key":"2022041907565483700_CIT0031","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","article-title":"The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase \u00bd trial","volume":"15","author":"Huttner","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2022041907565483700_CIT0032","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.vaccine.2009.09.135","article-title":"Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers","volume":"28","author":"Bernstein","year":"2009","journal-title":"Vaccine"},{"key":"2022041907565483700_CIT0033","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1182\/blood-2016-07-729756","article-title":"MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults","volume":"129","author":"La Rosa","year":"2017","journal-title":"Blood"},{"key":"2022041907565483700_CIT0034","doi-asserted-by":"crossref","first-page":"e1005276","DOI":"10.1371\/journal.ppat.1005276","article-title":"Arenavirus glycan shield promotes neutralizing antibody evasion and protracted infection","volume":"11","author":"Sommerstein","year":"2015","journal-title":"PLoS Pathog"},{"key":"2022041907565483700_CIT0035","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1172\/JCI200422374","article-title":"Kinetics of protective antibodies are determined by the viral surface antigen","volume":"114","author":"Pinschewer","year":"2004","journal-title":"J Clin Invest"},{"key":"2022041907565483700_CIT0036","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S1386-6532(02)00093-8","article-title":"Is there a formula for an effective CMV vaccine?","volume":"25","author":"Plotkin","year":"2002","journal-title":"J Clin Virol"},{"key":"2022041907565483700_CIT0037","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1182\/blood-2010-01-262089","article-title":"Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation","volume":"116","author":"Feuchtinger","year":"2010","journal-title":"Blood"},{"key":"2022041907565483700_CIT0038","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1038\/leu.2017.16","article-title":"Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT","volume":"31","author":"Neuenhahn","year":"2017","journal-title":"Leukemia"},{"key":"2022041907565483700_CIT0039","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1128\/JVI.00467-12","article-title":"Antibodies against the gH\/gL\/UL128\/UL130\/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin","volume":"86","author":"Fouts","year":"2012","journal-title":"J Virol"},{"key":"2022041907565483700_CIT0040","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1128\/JVI.01809-09","article-title":"Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH\/gL\/UL128-131A complex","volume":"84","author":"Macagno","year":"2010","journal-title":"J Virol"},{"key":"2022041907565483700_CIT0041","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1016\/j.vaccine.2012.05.049","article-title":"Immune markers and correlates of protection for vaccine induced immune responses","volume":"30","author":"Thakur","year":"2012","journal-title":"Vaccine"},{"key":"2022041907565483700_CIT0042","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/infdis\/jix086","article-title":"Higher T-cell responses induced by DNA\/rAd5 human immunodeficiency virus-1 preventive vaccine are associated with lower HIV-1 infection risk in an efficacy trial","volume":"215","author":"Janes","year":"2017","journal-title":"J Infect Dis"},{"key":"2022041907565483700_CIT0043","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1164\/rccm.201504-0733OC","article-title":"Polyfunctional T-cell signatures to predict protection from cytomegalovirus after lung transplantation","volume":"193","author":"Snyder","year":"2016","journal-title":"Am J Respir Crit Care Med"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaa121\/33098006\/jiaa121.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/8\/1399\/43387073\/jiaa121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/8\/1399\/43387073\/jiaa121.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T08:16:13Z","timestamp":1650356173000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/225\/8\/1399\/5821369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,21]]},"references-count":43,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,4,21]]},"published-print":{"date-parts":[[2022,4,19]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa121","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,15]]},"published":{"date-parts":[[2020,4,21]]}}}